T he year 2001 ended with a bang when biotech veteran Amgen (Thousand Oaks, CA) announced on December 16 that it would acquire Immunex (Seattle, WA) for $16 billion in shares and cash-the highest sum paid to date in a biotech-biotech acquisition. The Amgen-Immunex deal far outstripped other acquisitions made around that time, including Millennium Pharmaceuticals' (Cambridge, MA) purchase of COR Therapeutics (S. San Francisco, CA) and MedImmune's (Gaithersburg, MD) purchase of Aviron (Mountain View, CA). However, all three deals were made with a similar goal in mind-to acquire new products to help the companies accelerate earnings at the rates demanded by impatient investors. Whether Amgen paid too high a price remains in question.
Analysts have long predicted a wave of consolidation within the biotechnology industry. Few biotech companies are profitable, with most lacking marketed products or even the rich product pipelines needed for long-term survival. Following 2000's biotech "boom," however, many companies now have substantial capital raised from public or private markets. Strategically savvy companies have waited until equity has returned to more realistic levels before making the much-needed acquisitions to achieve critical mass.
The key driver behind the Immunex acquisition is Amgen's need for a suitably profitable follow-up to its blockbuster anemia treatment, Epogen, to continue to provide the 20-30% growth in profits promised to shareholders. Although Amgen has other products on or close to the market, only Neupogen, Epogen, and the second-generation anemia treatment Aranesp are potential blockbusters. Immunex is essentially a one-drug company, its "golden egg" being the rheumatoid arthritis treatment Enbrel, which generated sales of $546 million in the last three quarters of 2001 alone, up 19% from the same period in the previous year. The drug, which mops up excess tumor necrosis factor (TNF), is on track to become a blockbuster in 2002. Amgen is optimistic that Enbrel, which could gain additional indications for the treatment of psoriatic arthritis, ankylosing spondylitis, and psoriasis, could reach peak sales of $3 billion by 2005.
Analysts appear to be split, however, over whether Amgen can achieve such sales and thereby justify the premium paid-some four times predicted peak sales. Geoffrey Harris, biotech analyst with UBS Warburg in New York, points out that Enbrel's profits will continue to be shared with American Home Products, a major shareholder of Immunex (and now holder of 8% of the new company), further increasing the relative premium paid (possibly some 8 times sales). Investors are also dubious, and Amgen's share price continues to trade around $54, some 15% lower than before the announcement. Joe Dougherty, biotech analyst at Lehman Brothers (New York), is more bullish, arguing that "with work" Amgen could indeed achieve $3 billion sales by 2005. Amgen has considerable expertise in the manufacture of proteins, and has not fallen foul of the many problems faced by other protein manufacturers, says Dougherty. For example, Johnson & Johnson recently sent a letter to European doctors warning them of a rare red blood-cell disorder in patients treated with erythropoietin. The side effect, which appears to occur with all formulations of erythropoietin, may be linked to an immune reaction to the drug, but has been seen less frequently with Epogen.
Whether or not Enbrel will fulfill Amgen's hopes of delivering sales growth in the mid-20% range annually, Amgen's acquisition of Immunex-85% of which will be paid in shares and 15% in cash-will create a biotech colossus with a market capital value of over $70 billion and potentially $5.5 billion in revenue in 2002. The Immunex acquisition will place Amgen in the same league as mid-cap pharmaceutical compa- T he political implications of results purporting to show that DNA from commercial transgenic crops has entered landraces of maize in Mexico are already starting to be felt, even though the issue remains unresolved scientifically. Though the political response in Mexico itself has been relatively sober and considered, the precautionary instincts of Europe's politicians may mean the loss of yet another opportunity to lift the de facto moratorium on commercial plantings of GM crops in Europe.
Amgen's big-ticket play for Immunex Amgen now moves up ranks among pharmaceutical players
The controversy over Mexican maize stems from work performed by David Quist and Ignacio Chapela, researchers at the University of California, Berkeley, whose analyses indicated that DNA sequences presumed to have come from commercial transgenic maize had found their way into a small number of farmer-bred maize plants in Mexico. The researchers conjectured that the flow of transgenes might represent a threat to biological diversity. Their paper, published in Nature at the end of November after an extensive period of review and revision, stimulated environmental groups to urge governments to step up their restrictions on GM crop activity (Nat. Biotechnol. 20, 3, 2002) .
Such reactions reflect genuine concerns about threats to genetic diversity, especially in areas such as Mexico which, as the origin of maize-based agriculture, is the center of genetic diversity for that crop. At the beginning of December, the Mexican senate took up Greenpeace's cry and called for its Department of Agriculture to stop all Mexican imports of US corn. President Vicente Fox and his government have resisted these calls. Luis Herrera-Estrella, Director of CINVESTAV Irapuato, Mexico's leading center for plant biotechnology, believes that the Mexican government will not be rushed into decisions until scientific investigations are complete. "People generally are not really worried about this and, unless there is huge amount of public pressure, the political response in Mexico will be rational," says Herrera. That is not to say that that there are no implications within Mexico. Its own moratorium on commercial planting of GM materials was due to end in April 2002 but will now probably be extended, according to Herrera.
The real extent of any gene flow from commercial transgenics in Mexico is still unclear. Continuing work at the International Maize and Wheat Improvement Center (CIMMYT; El Batan, Mexico) has so far not turned up any evidence of the suspect transgenic sequence in over 40 samples from CIMMYT's gene bank. The center's latest analyses, reported in a press release in midDecember, indicated that it has also not found the promoter in 42 samples of seeds collected in 2000 from the same region, Oaxaca, in which the Berkeley researchers had operated.
At the same time, Mexican government laboratories seem to have confirmed Quist and Chapela's basic finding. A preliminary announcement was made in September by the Mexican Instituto Nacional de Ecologia that landrace maize collected in Oaxaca and elsewhere contained transgenes. Although those results might have been due to contamination of the field or laboratory samples, Herrera says it looks as if at least some of the positive results were real. In other words, as widely anticipated by environmentalists and biotechnologists alike, gene flow has occurred between the various types of maize present in Mexico.
Confusingly, however, the data from the Berkeley study may be scientifically flawed, perhaps seriously. Peggy Lemaux from the Department of Plant and Microbial Biology at the University of California, Berkeley is just one of the researchers who are aware that scientists from various institutions are preparing scientific challenges to the data in Quist and Chapela's paper. "Graduate students and postdocs spotted problems with the papers," she explained. "The methods used in their paper are common practice to students, and seeing possible errors was not difficult." She believes that the arguments have scientific validity and that both sides of the story need to be heard. People are entitled to different views on the desirability of GM crops, she says, but they should start consideration of the issues from solid data. "We must address the issues brought up by the Biotechnol. 20, 11, 2002) . The COR deal provided Millennium with a badly needed blockbuster product, the anti-clotting agent Integrilin, and a sales and marketing team. Millennium had just one drug on the market, Campath, the rights to which it recently returned to its developer, Ilex Oncology. MedImmune likewise forked out $1.5 billion on December 4, 2001, for fellow vaccine developer Aviron, gaining the as-yet-unapproved nasal-spray flu vaccine FluMist (Nat. Biotechnol. 20, 11, 2002) . MedImmune had just one marketed drug, Synagis, a treatment for serious respiratory tract infections in infants, whose sales are expected to plateau, according to Lehman Brothers.
The emphasis on product-focused deals might also explain why much of the acquisition activity has occurred in the United States and not in Europe. Many more US companies have drugs in later stages of development, which make attractive targets, says Schmidt. Other companies known to be considering becoming acquirers include Chiron, Biogen, and Genentech, which have weak product pipelines. Indeed, in early January Chiron (Emeryville, CA) purchased cancer drug manufacturer Matrix Pharmaceuticals (Fremont, CA), ostensibly for access to an experimental cancer drug tezacitabine, which will move into phase II trials.
The year 2002 could see considerably greater merger and acquisition activity within the sector.
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